(Q30765293)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

review article

1 reference

title

Primary brain tumours in adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

4

Jean-Yves Delattre

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

3

Antoine F Carpentier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

2

Khe Hoang-Xuan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

language of work or name

English

0 references

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

volume

361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

page(s)

323-331

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

issue

9354

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

RESPONSE: Re: Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality

17 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Glioblastomas with an oligodendroglial component: a pathological and molecular study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

What is an oligodendroglioma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

OLIG2 as a specific marker of oligodendroglial tumour cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Malignant glioma: genetics and biology of a grave matter.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Molecular genetic evidence for subtypes of oligoastrocytomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Gliomagenesis: genetic alterations and mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Long-term outcome of low-grade oligodendroglioma and mixed glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Imaging of low- and intermediate-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Intraoperative cortical mapping as a guide to the surgical resection of gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Low-grade oligodendroglioma responds to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

1 reference

7 January 2021

Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Methylphenidate therapy improves cognition, mood, and function of brain tumor patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Incidence of neurologic deficits and rehabilitation of patients with brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Extent of resection in malignant gliomas: a critical summary.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Successful chemotherapy for recurrent malignant oligodendroglioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

The treatment of anaplastic oligodendrogliomas and mixed gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Primary Central Nervous System Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

The clinical spectrum of ocular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Primary CNS lymphoma: findings outside the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Combined modality therapy for primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Long-term survival in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Treatment for primary CNS lymphoma: the next step

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

Second-line treatment for primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912328-8

7 January 2021

10.1016/S0140-6736(03)12328-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559880%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference